Plant-based expression of a partially humanized neutralizing monoclonal IgG directed against an immunodominant epitope on the ricin toxin A subunit

Vaccine

Volumn 30, Issue 7, 2012, Pages 1239-1243

  O'Hara, Joanne M ^a,b   Whaley, Kevin ^c   Pauly, Michael ^c   Zeitlin, Larry ^c   Mantis, Nicholas J ^a,b  

^a WADSWORTH CENTER   (United States)

^b STATE UNIVERSITY OF NEW YORK   (United States)

^c Mapp Biopharmaceutical Inc   (United States)

Author keywords

Antibody; Biodefense; Therapeutics; Toxin

Indexed keywords

EPITOPE; GD12 MONOCLONAL ANTIBODY; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN LIGHT CHAIN; MONOCLONAL ANTIBODY; RICIN A; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY SPECIFICITY; ARTICLE; CHIMERA; CONTROLLED STUDY; CYTOTOXICITY TEST; EXPRESSION VECTOR; FEMALE; IMMUNOTHERAPY; INTOXICATION; LD 50; MOUSE; NICOTIANA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PURIFICATION; RICIN INTOXICATION;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, NEUTRALIZING; EPITOPES; FEMALE; GENE EXPRESSION; HUMANS; IMMUNIZATION, PASSIVE; IMMUNODOMINANT EPITOPES; IMMUNOGLOBULIN G; INJECTIONS, INTRAPERITONEAL; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; POISONING; RECOMBINANT FUSION PROTEINS; RICIN; TOBACCO;

EID: 84856567770     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.12.058     Document Type: Article

References (21)

1. Olsnes S. The history of ricin, abrin and related toxins. Toxicon 2004, 44(September (4)):361-370.
2. Stirpe F. Ribosome-inactivating proteins. Toxicon 2004, 44(September (4)):371-383.
3. Endo Y., Mitsui K., Motizuki M., Tsurugi K. The mechanism of action of ricin and related toxins on eukaryotic ribosomes. J Biol Chem 1987, 262:5908-5912.
4. Baenziger J.U., Fiete D. Structural determinants of Ricinus communis agglutinin and toxin specificity for oligosaccharides. J Biol Chem 1979, 254(19):9795-9799.
5. McGuinness C.R., Mantis N.J. Characterization of a novel high-affinity monoclonal immunoglobulin G antibody against the ricin B subunit. Infect Immun 2006, 74(June (6)):3463-3470.
6. Neal L.M., O'Hara J., Brey R.N., Mantis N.J. A monoclonal immunoglobulin G antibody directed against an immunodominant linear epitope on the ricin A chain confers systemic and mucosal immunity to ricin. Infect Immun 2010, 78(January (1)):552-561.
7. O'Hara J.M., Neal L.M., McCarthy E.A., Kasten-Jolly J.A., Brey R.N., Mantis N.J. Folding domains within the ricin toxin A subunit as targets of protective antibodies. Vaccine 2010, 28(August):7035-7046.
8. Yermakova A., Mantis N.J. Protective immunity to ricin toxin conferred by antibodies against the toxin's binding subunit (RTB). Vaccine 2011, 29(August):7925-7935.
9. Castelletti D., Fracasso G., Righetti S., Tridente G., Schnell R., Engert A., et al. A dominant linear B-cell epitope of ricin A-chain is the target of a neutralizing antibody response in Hodgkin's lymphoma patients treated with an anti-CD25 immunotoxin. Clin Exp Immunol 2004, 136(May (2)):365-372.
10. Lemley P.V., Amanatides P., Wright D.C. Identification and characterization of a monoclonal antibody that neutralizes ricin toxicity in vitro and in vivo. Hybridoma 1994, 13(5):417-421.
11. Pratt T.S., Pincus S.H., Hale M.L., Moreira A.L., Roy C.J., Tchou-Wong K.M. Oropharyngeal aspiration of ricin as a lung challenge model for evaluation of the therapeutic index of antibodies against ricin A-chain for post-exposure treatment. Exp Lung Res 2007, 33(October-November (8-9)):459-481.
12. Prigent J., Panigai L., Lamourette P., Sauvaire D., Devilliers K., Plaisance M., et al. Neutralising antibodies against ricin toxin. PLoS One 2011, 6(5):e20166.
13. Roche J.K., Stone M.K., Gross L.K., Lindner M., Seaner R., Pincus S.H., et al. Post-exposure targeting of specific epitopes on ricin toxin abrogates toxin-induced hypoglycemia, hepatic injury, and lethality in a mouse model. Lab Invest 2008, 88(November (11)):1178-1191.
14. Essono S., Frobert Y., Grassi J., Crèminon C., Boquet D. A general method allowing the design of oligonucleotide primers to amplify the variable regions from immunoglobulin cDNA. J Immunol Methods 2003, 279(1-2):251-266.
15. Hiatt A., Pauly M. Monoclonal antibodies from plants: A new speed record. Proc Natl Acad Sci 2006, 103(October (40)):14645-14646.
16. Strasser R., Stadlmann J., Schähs M., Stiegler G., Quendler H., Mach L., et al. Generation of glyco-engineered Nicotiana benthamiana for the production of monoclonal antibodies with a homogeneous human-like N-glycan structure. Plant Biotechnol J 2008, 6(4):392-402.
17. Pincus S.H., Eng L., Cooke C.L., Maddaloni M. Identification of hypoglycemia in mice as a surrogate marker of ricin toxicosis. Comp Med 2002, 52(December (6)):530-533.
18. Whaley K.J., Hiatt A., Zeitlin L. Emerging antibody products and Nicotiana manufacturing. Hum Vaccin 2011, 7(March (3)).
19. Mantis NJ, Morici LA, Roy CJ. Mucosal vaccines for biodefense. Curr Top Microbiol Immunol, in press [online in April].
20. Pogue G.P., Vojdani F., Palmer K.E., Hiatt E., Hume S., Phelps J., et al. Production of pharmaceutical-grade recombinant aprotinin and a monoclonal antibody product using plant-based transient expression systems. Plant Biotechnol J 2010, 8(June (5)):638-654.
21. Vitetta E.S., Smallshaw J.E., Coleman E., Jafri H., Foster C., Munford R., et al. A pilot clinical trial of a recombinant ricin vaccine in normal humans. Proc Natl Acad Sci USA 2006, 103(February (7)):2268-2273.